












The late stage of COPI vesicle fission requires shorter forms of phosphatidic 
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Supplementary Figure 1. Effects of PA in COPI transport.  (a) Schematic showing the two general types of membrane 
curvature during vesicle formation, with positive curvature promoted by “inverted-cone” lipid geometry and negative 
curvature promoted by “cone” lipid geometry.  (b) Schematic showing the budding and fission stage of COPI vesicle 
formation, with fission further sub-divided into early versus late, as defined by the roles of different lipid enzymes.  (c) 
Schematic showing PA with saturated acyl chains.  (d) Schematic showing PA with single unsaturation in both acyl 
chains, having cis double bond at carbon position 9.  (e) Efficiency of siRNA treatment assessed by the expression of 
Cy3-labeled scrambled oligonucleotide.  Representative image is shown above, bar = 10 uM.  Quantitation is shown 
below, n= 3 independent experiments mean ± s.e.m, two-tailed Student t-test, ***P<0.001.  Source data are provided as a 
Source Data file.  (f) Confirmation of reduced LPAAT level upon siRNA against LPAAT.  HeLa cells were subjected 
to the siRNA treatment followed by immunoblotting for LPAAT  (g) Confirmation of reduced PLD2 level upon siRNA 






Supplementary Figure 2. Effects of unsaturated PA in COPI transport.  (a) HeLa cells were treated with siRNA 
against LPAAT to inhibit COPI transport, with rescue using different forms of PA as indicated.  COPI transport in cells 
was tracked by examining the colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi marker 
(giantin) at time points as indicated.  Representative images are shown, bar = 5um.  (b) HeLa cells were treated with 
siRNA against PLD2 to inhibit COPI transport, with rescue using different forms of PA as indicated.  COPI transport in 
cells was tracked by examining the colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi 
marker (giantin) at time points as indicated.  Representative images are shown, bar = 5um.  (c) Schematic showing PA 
with polyunsaturation in one acyl chain, with conformation as suggested by the recent study on clathrin vesicle fission.  
(d) HeLa cells were treated with siRNA against LPAAT to inhibit COPI transport, with rescue using PA form as 
indicated.  COPI transport in cells was tracked by examining the colocalization of a COPI-dependent cargo protein 
(VSVG-KDELR) with Golgi marker (giantin) at time points as indicated.  Representative images are shown, bar = 5um.  
(e) HeLa cells were treated with siRNA against PLD2 to inhibit COPI transport, with rescue using PA form as indicated.  
COPI transport in cells was tracked by examining the colocalization of a COPI-dependent cargo protein (VSVG-KDELR) 






Supplementary Figure 3. Effects of short PA in COPI transport.  (a, b) HeLa cells were treated with siRNA against 
PLD2 to inhibit COPI transport, with rescue using different forms of PA as indicated.  COPI transport in cells was tracked 
by examining the colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi marker (giantin) at time 
points as indicated.  Representative images are shown, bar = 5um.  (c) HeLa cells were treated with siRNA against 
LPAAT to inhibit COPI transport, with rescue using different forms of PA as indicated.  COPI transport in cells was 
tracked by examining the colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi marker (giantin) 





Supplementary Figure 4. Effects of DAG in COPI transport.  (a) Confirmation of reduced LPP3 level upon siRNA 
against LPP3.  HeLa cells were subjected to the siRNA treatment followed by immunoblotting for LPP3.  Note that LPP3 
appears as multiple bands due to its glycosylation.  (b) HeLa cells were treated with siRNA against LPP3 to inhibit COPI 
transport, with rescue using different forms of DAG as indicated.  COPI transport in cells was tracked by examining the 
colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi marker (giantin) at time points as 
indicated.  Representative images are shown, bar = 5um.  (c) HeLa cells were treated with siRNA against LPP3 to inhibit 
COPI transport, with rescue using DAG form as indicated.  COPI transport in cells was tracked by examining the 
colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi marker (giantin) at time points as 
indicated.  Representative images are shown, bar = 5um.  (d) HeLa cells were treated with siRNA against LPP3 to inhibit 
COPI transport, with rescue using DAG form as indicated.  COPI transport in cells was tracked by examining the 
colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi marker (giantin) at time points as 




Supplementary Figure 5. PA and DAG have distinct roles in COPI transport.  Quantitative data are shown as mean ± 
s.e.m.   Significance was tested using the two-tailed Student t-test, ** P<0.01, *** P<0.001, NS P>0.05.  Source data are 
provided as a Source Data file. 
(a) Golgi membrane with reduced PLD2 level was used for the vesicle reconstitution system, with rescue using either 
short PA or DAG; n=5 independent experiments.  (b) Golgi membrane with reduced LPP3 level was used for the vesicle 
reconstitution system, with rescue using either short PA or DAG; n=5 independent experiments.  (c) HeLa cells were 
treated with siRNA against PLD2 with rescue using either short PA or DAG.  COPI transport was then quantified, n=4 
independent experiments.  (d) HeLa cells were treated with siRNA against PLD2 with rescue using either short PA or 
DAG.  Colocalization of a COPI-dependent cargo protein (VSVG-KDELR) with Golgi marker (giantin) was then 
assessed.  Representative images are shown, bar = 5um.  (e) HeLa cells were treated with siRNA against LPP3 with 
rescue using either short PA or DAG.  COPI transport was then quantified, n=4 independent experiments.  (f) HeLa cells 
were treated with siRNA against LPP3 with rescue using either short PA or DAG.  Colocalization of a COPI-dependent 
cargo protein (VSVG-KDELR) with Golgi marker (giantin) was then assessed.  Representative images are shown, bar = 
5um.  (g) Golgi membrane with reduced PLD2 or LPP3 level was used for the vesicle reconstitution system.  Rescue was 
performed using short PC; n=3 independent experiments. 
 
Supplementary Figure 6. PA and DAG with mixed acyl-chain lengths in COPI vesicle formation.  Quantitative data 
are shown as mean ± s.e.m.  Source data are provided as a Source Data file. 
(a) Schematic of PA with mixed acyl-chain lengths.  (b) Golgi membrane with reduced PLD2 level was used for the COPI 
vesicle reconstitution system, with rescue of vesicle formation using forms of PA as indicated; n=3 independent 
experiments.  (c) Schematic of DAG with mixed acyl-chain lengths.  (d) Golgi membrane with reduced LPP3 level was 





Supplementary Figure 7. Analysis of Golgi membrane from cells fed with short PA.  HeLa cells were fed with short 
(2C10:0) PA, and then Golgi membrane was isolated.  After lipid extraction, quadrupole time of flight MS/MS detection 
was performed.  (a) Collision induced dissociation mass spectrometry of PA in the negative mode and DAG in the 
positive mode show the expected fragmentation patterns, including diagnostic ions for decanoyl PA (m/z 479 to 171) and 
decanoyl DAG (m/z 418 to 229), which were used to track these compounds in subsequent cellular experiments.  (b) 
Complex cellular lipids eluting into methanol were injected followed by specific tracking of PA and DAG based on the 
indicated MS/MS signals.  Two representative experiments (out of five) are shown.  (c) Golgi membrane subjected to the 
COPI vesicle reconstitution system shows enhanced conversion of short PA to short DAG.  A representative experiment 
(out of two) with three replicates is shown, with each set comparing PA-fed Golgi membrane either without or with 







Supplementary Figure 8. Lipid enzymes associate with COPI-related factors.  (a) BARS associate with PLD2 and 
LPP3.  Whole cell lysates from HeLa cells were immunoprecipitated for either PLD2 or LPP3 followed by 
immunoblotting for BARS.  Immunoblotting for PLD2 or LPP3 confirms the presence of these enzymes in the 
immunoprecipitated.  HA-tagged form of LPP3 was used because antibody against endogenous LPP3 was inefficient for 
immunoprecipitation. (b) The GTP-bound form is required for ARF1 to bind simplified liposomes.  ARF1 in either GTP 
or GDP form was incubated with different simplified liposomes as indicated, followed by centrifugation to obtain pellet 
(P, membrane-bound) or soluble (S) fractions. 
 
 
Supplementary Figure 9. Characterization of liposomes.  (a) Liposome leakage assay confirming that simplified 
liposomes are functionally intact.  Liposomes with 70% DOPC and 30% of DAG form as indicated were loaded with 
calcium, and then monitored for leakage out of liposomes using fluo-4, a calcium-sensitive fluorophore, which was placed 
outside of liposomes.  No significant leakage was observed until a detergent (Octyl -D-glucopyranoside) was added to 
the incubation.  (b) High-resolution cryo-EM confirming that simplified liposomes, with lipid composition indicated, form 
membrane bilayers, bar = 100 nm.  A higher magnification of the inset area is shown on right. 
 
Supplementary Figure 10. Key proteins and lipids driving COPI vesicle fission.  Our results 
suggest that PA of varying forms generated by LPAAT- promotes early fission, while short PA 
generated by PLD2 followed by short DAG generated by LPP3 promote late fission.  Moreover, 
BARS acts in conjunction with PA to deform membrane, with short PA best promoting the 
vesiculation of BARS, while ARF1 and ARFGAP1 act in conjunction with PA and DAG to 


















All  reactions were  carried  out  under  a  nitrogen  atmosphere using oven‐dried  glassware  and  using 
standard  Schlenk  techniques.  Reaction  temperature  refers  to  the  temperature  of  the  oil  bath.  All 
reagents and catalysts were purchased from Sigma‐Aldrich, Acros, J&K Scientific and TCI Europe and 








gel  type  SiliaFlash  P60  (230  –  400 mesh).GC‐MS measurements were  performed with  an HP  6890 
series gas chromatography system equipped with an HP1 or HP5 column (Agilent Technologies, Palo 
Alto,  CA),  and  equipped  with  an  HP  5973  mass  sensitive  detector.  High  resolution  mass  spectra 
(HRMS) were recorded on a Thermo Scientific LTQ Orbitrap XL. (ESI+, ESI‐ and APCI). 1H‐, 13C‐ and 31P‐
NMR spectra were recorded on a Varian AMX400 (400, 100.6 and 162 MHz, respectively) using CDCl3 
as  solvent  unless  stated  otherwise.  Chemical  shift  values  are  reported  in  ppm  with  the  solvent 
resonance  as  the  internal  standard  (CDCl3:  δ  7.26  for  1H,  δ  77.16  for  13C).  Data  are  reported  as 
follows: chemical shifts (δ), multiplicity (s = singlet, d = doublet, dd = double doublet, ddd = double 
double  doublet,  td  =  triple  doublet,  t  =  triplet,  q  =  quartet,  b  =  broad,  m  =  multiplet),  coupling 
constants  J  (Hz),  and  integration.  Enantiomeric  excesses were  determined  by  chiral  HPLC  analysis 
using a Shimadzu LC‐ 10ADVP HPLC instrument equipped with a Shimadzu SPD‐M10AVP diode‐array 

































































(R)‐tert‐butyldimethyl(oxiran‐2‐ylmethoxy)silane  (2).  To  a  stirred  solution  of  imidazole  (4.5 
g, 66 mmol, 2.2 equiv) in CH2Cl2 (120 mL) was added TBSCl (5.0 g, 33 mmol, 1.1 equiv), resulting in a 
thick  suspension  that was  cooled  to 0  °C  (ice/water bath).  (S)‐glycidol  (2.2 g,  2 mL,  30 mmol) was 
added  to  in  a  dropwise  fashion,  after  complete  addition  the mixture was  allowed  to warm  up  to 
room temperature and was stirred for 16 h. The suspension was filtered and washed with CH2Cl2, the 






added palmitic acid  (513 mg, 2 mmol),  immediately  turning  the mixture dark brown. The resulting 
solution  was  allowed  to  stir  for  15  minutes  before  the  solvent  was  evaporated.  The  dark  brown 
residue was  resolubilized by  the addition of DIPEA  (0.35 mL, 2 mmol, 1 equiv.)  in THF  (0.2 mL),  to 
which epoxide 2  in  THF  (0.3 mL) was  added. After  20 h,  full  conversion was observed  via  1H‐NMR 
spectroscopy,  whereupon  the  reaction  mixture  was  concentrated.  The  resulting  brown  solid  was 
dissolved  in  heptane  (4  mL)  to  which  decanoic  acid  (414  mg,  2.4  mmol,  1.2  equiv.)  and  DMAP 
(12 mg, 0.1 mmol, 5 mol%) were added. The resulting mixture was cooled  to 0  °C  (ice/water bath) 
and DCC (495 mg, 2.4 mmol, 1.2 equiv.) was added in one portion. After 16 h the entire mixture was 















(R)‐1‐((tert‐butyldimethylsilyl)oxy)‐3‐(decanoyloxy)propan‐2‐yl  palmitate  (3b)  (380  mg,  2  mmol). 
















in  CH2Cl2  and  subsequently  cooled  to  0  °C  (ice/water  bath).  CH3CN∙BF3  (0.275 mL,  0.33 mmol,  1.1 


























(R)‐3‐((bis(benzyloxy)phosphoryl)oxy)‐2‐(decanoyloxy)propyl  palmitate  (5a).  Diacylglycerol  4a 
(160 mg,  0.33  mmol)  was  dissolved  in  CH2Cl2  (1.3  mL),  dibenzyl  N,N‐diisopropylphosphoramidite 
(0.145 mL,  0.43 mmol,  1.3 equiv) was  added and  the mixture was  cooled  to 0  °C  (ice/water bath). 
4,5‐Dicyanoimidazole  (47 mg, 0.4 mmol, 1.2 equiv) was added  in one portion and the mixture was 
allowed to stir for 30 min before a 5 M solution of t‐BuOOH (0.1 mL, 0.5 mmol, 1.5 equiv) was added 
in  a  dropwise  fashion.  After  30  minutes  the  mixture  was  diluted  with  ether  and  poured  on  a 
saturated  NaHCO3  solution.  The  layers  were  separated,  and  the  organic  layer  was  subsequently 
washed  with  1 M  HCl  and  brine,  dried  over MgSO4  and  concentrated  in  vacuo.  The  product  was 
further  purified  by  column  chromatography  (15%  EtOAc  in  pentane)  to  afford  the  desired 




































(R)‐2‐(decanoyloxy)‐3‐(palmitoyloxy)propyl  hydrogen  phosphate  (6a).  A  solution  of  dibenzyl 
phosphate 5a (52 mg, 70 µmol) in methanol (2 mL) was degassed with freeze‐pump thaw technique. 
10  w%  Pd/C  (4.3 mg,  4  µmol,  5  mol%)  was  added  to  the  degassed  mixture  under  nitrogen 
atmosphere. Subsequently a hydrogen atmosphere was established, and the suspension was allowed 
to  stir  for  16 h.  The  black mixture was  diluted with  Et2O  and  filtered  over  celite,  the  filtrate  was 
concentrated  and  further  purified by  column  chromatography  (20% MeOH and  1%  Et3N  in  CHCl3). 
The desired Et3NH+ phosphate salt 6a (28 mg, 50 µmol, 71%) was isolated as an oil. A general remark 











(R)‐3‐(decanoyloxy)‐2‐(palmitoyloxy)propyl  hydrogen  phosphate  (6b)  (45  mg,  60  µmol).  This 
compound  was  prepared  with  the  same  synthetic  procedure  that  was  used  for 
(R)‐2‐(decanoyloxy)‐3‐(palmitoyloxy)propyl hydrogen phosphate (6a) (26 mg, 46 µmol, 76%). 
 
1H NMR (400 MHz, Chloroform‐d) δ 5.22 (s, 1H), 4.37 (d, J = 11.9 Hz, 1H), 4.16 (dd, J = 12.0, 6.7 Hz, 
1H), 4.08 – 3.85 (m, 2H), 3.09 (s, 6H), 2.27 (q, J = 7.4 Hz, 4H), 1.65 – 1.50 (m, 5H), 1.26 (br s, 45H), 
0.87 (t, J = 6.6 Hz, 6H). 
13C NMR (101 MHz, Chloroform‐d) δ 173.5, 173.2, 70.5, 65.5, 62.9, 45.8, 34.4, 34.2, 32.06, 32.0, 29.7, 
29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.5, 29.5, 29.4, 29.3, 25.1, 25.0, 22.8, 22.8, 14.2, 8.7. 
31P NMR (162 MHz, Chloroform‐d) δ 1.54. 
HRMS‐ESI‐ (m/z): [M]‐ calculated for C29H56O8P, 563.372; found, 563.372 
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Supplementary figure 11: 1H NMR spectra for 4a 
 
Supplementary figure 12: 13C NMR spectra for 4a 
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Supplementary figure 13: HRMS spectra for 4a 
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Supplementary figure 14: 1H NMR spectra for 4b 
 
Supplementary figure 15: 13C NMR spectra for 4b 
 
 
 
 
Supplementary figure 16: HRMS spectra for 4b 
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Supplementary figure 17: 1H NMR spectra for 6a 
 
Supplementary figure 18: 13C NMR spectra for 6a 
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Supplementary figure 19: 31P NMR spectra for 6a 
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Supplementary figure 20: HRMS spectra for 6a 
 
 
 
Supplementary figure 21: 1H NMR spectra for 6b 
 
Supplementary figure 22: 13C NMR spectra for 6b 
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Supplementary figure 23: 31P NMR spectra for 6b 
 
 
Supplementary figure 24: HRMS spectra for 6b 
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